Cargando…

Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study

We aimed to compare the overall survival (OS) of patients with bone metastases (BM) from solid tumors after standard‐dose radiotherapy ([RT]; 30 Gy administered in 10 fractions; EQD(2Gy) = 32.5 Gy) and dose‐escalated RT (EQD(2Gy) > 32.5 Gy). We retrospectively reviewed the clinical charts of 1795...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Yung‐Chih, Lin, Chien‐Yu, Pai, Ping‐Ching, Tseng, Chen‐Kan, Hsieh, Cheng‐En, Chang, Kai‐Ping, Hsu, Cheng‐Lung, Liao, Chun‐Ta, Wang, Chun‐Chieh, Chin, Shy‐Chyi, Yen, Tzu‐Chen, Ho, Tsung‐Ying, Hong, Ji‐Hong, Lei, Kin‐Fong, Chang, Joseph Tung‐Chieh, Tsang, Ngan‐Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603838/
https://www.ncbi.nlm.nih.gov/pubmed/28809463
http://dx.doi.org/10.1002/cam4.1150
_version_ 1783264775858290688
author Chou, Yung‐Chih
Lin, Chien‐Yu
Pai, Ping‐Ching
Tseng, Chen‐Kan
Hsieh, Cheng‐En
Chang, Kai‐Ping
Hsu, Cheng‐Lung
Liao, Chun‐Ta
Wang, Chun‐Chieh
Chin, Shy‐Chyi
Yen, Tzu‐Chen
Ho, Tsung‐Ying
Hong, Ji‐Hong
Lei, Kin‐Fong
Chang, Joseph Tung‐Chieh
Tsang, Ngan‐Ming
author_facet Chou, Yung‐Chih
Lin, Chien‐Yu
Pai, Ping‐Ching
Tseng, Chen‐Kan
Hsieh, Cheng‐En
Chang, Kai‐Ping
Hsu, Cheng‐Lung
Liao, Chun‐Ta
Wang, Chun‐Chieh
Chin, Shy‐Chyi
Yen, Tzu‐Chen
Ho, Tsung‐Ying
Hong, Ji‐Hong
Lei, Kin‐Fong
Chang, Joseph Tung‐Chieh
Tsang, Ngan‐Ming
author_sort Chou, Yung‐Chih
collection PubMed
description We aimed to compare the overall survival (OS) of patients with bone metastases (BM) from solid tumors after standard‐dose radiotherapy ([RT]; 30 Gy administered in 10 fractions; EQD(2Gy) = 32.5 Gy) and dose‐escalated RT (EQD(2Gy) > 32.5 Gy). We retrospectively reviewed the clinical charts of 1795 patients (median age, 62.3 years; age range, 18–96 years) with BM from solid tumors who were referred for RT to our institute between 2000 and 2013. These patients were assigned to the standard‐dose (n = 1125; 63%) and dose‐escalated (n = 670; 37%) RT groups. OS, estimated as the duration between the first RT session and death, served as the main outcome measure. The dose‐escalated RT group had a significantly better OS than the standard‐dose RT group (P = 0.000). After allowing potential confounders in multivariate analysis, the RT dose retained its independent association with OS (hazard ratio [HR], 0.837; 95% confidence interval [CI], 0.753–0.929, P = 0.001). After propensity score matching of the baseline characteristics of both groups, RT dose retained its independent association with OS (HR, 0.887; 95% CI, 0.737–0.951; P = 0.011) on multivariate analysis. Dose‐escalated RT exerted more favorable effects on OS in patients with non‐lung cancer, those without multiple metastases, those without symptoms, and those with favorable prognosis. Dose‐escalated RT was significantly associated with better OS in patients with BM from solid malignancies, particularly among those with non‐lung cancer, those without multiple metastases, those without symptoms, and those with favorable prognosis.
format Online
Article
Text
id pubmed-5603838
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56038382017-09-20 Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study Chou, Yung‐Chih Lin, Chien‐Yu Pai, Ping‐Ching Tseng, Chen‐Kan Hsieh, Cheng‐En Chang, Kai‐Ping Hsu, Cheng‐Lung Liao, Chun‐Ta Wang, Chun‐Chieh Chin, Shy‐Chyi Yen, Tzu‐Chen Ho, Tsung‐Ying Hong, Ji‐Hong Lei, Kin‐Fong Chang, Joseph Tung‐Chieh Tsang, Ngan‐Ming Cancer Med Clinical Cancer Research We aimed to compare the overall survival (OS) of patients with bone metastases (BM) from solid tumors after standard‐dose radiotherapy ([RT]; 30 Gy administered in 10 fractions; EQD(2Gy) = 32.5 Gy) and dose‐escalated RT (EQD(2Gy) > 32.5 Gy). We retrospectively reviewed the clinical charts of 1795 patients (median age, 62.3 years; age range, 18–96 years) with BM from solid tumors who were referred for RT to our institute between 2000 and 2013. These patients were assigned to the standard‐dose (n = 1125; 63%) and dose‐escalated (n = 670; 37%) RT groups. OS, estimated as the duration between the first RT session and death, served as the main outcome measure. The dose‐escalated RT group had a significantly better OS than the standard‐dose RT group (P = 0.000). After allowing potential confounders in multivariate analysis, the RT dose retained its independent association with OS (hazard ratio [HR], 0.837; 95% confidence interval [CI], 0.753–0.929, P = 0.001). After propensity score matching of the baseline characteristics of both groups, RT dose retained its independent association with OS (HR, 0.887; 95% CI, 0.737–0.951; P = 0.011) on multivariate analysis. Dose‐escalated RT exerted more favorable effects on OS in patients with non‐lung cancer, those without multiple metastases, those without symptoms, and those with favorable prognosis. Dose‐escalated RT was significantly associated with better OS in patients with BM from solid malignancies, particularly among those with non‐lung cancer, those without multiple metastases, those without symptoms, and those with favorable prognosis. John Wiley and Sons Inc. 2017-08-15 /pmc/articles/PMC5603838/ /pubmed/28809463 http://dx.doi.org/10.1002/cam4.1150 Text en © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Chou, Yung‐Chih
Lin, Chien‐Yu
Pai, Ping‐Ching
Tseng, Chen‐Kan
Hsieh, Cheng‐En
Chang, Kai‐Ping
Hsu, Cheng‐Lung
Liao, Chun‐Ta
Wang, Chun‐Chieh
Chin, Shy‐Chyi
Yen, Tzu‐Chen
Ho, Tsung‐Ying
Hong, Ji‐Hong
Lei, Kin‐Fong
Chang, Joseph Tung‐Chieh
Tsang, Ngan‐Ming
Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
title Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
title_full Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
title_fullStr Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
title_full_unstemmed Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
title_short Dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
title_sort dose‐escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score‐matched study
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603838/
https://www.ncbi.nlm.nih.gov/pubmed/28809463
http://dx.doi.org/10.1002/cam4.1150
work_keys_str_mv AT chouyungchih doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT linchienyu doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT paipingching doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT tsengchenkan doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT hsiehchengen doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT changkaiping doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT hsuchenglung doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT liaochunta doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT wangchunchieh doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT chinshychyi doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT yentzuchen doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT hotsungying doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT hongjihong doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT leikinfong doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT changjosephtungchieh doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy
AT tsangnganming doseescalatedradiationtherapyisassociatedwithbetteroverallsurvivalinpatientswithbonemetastasesfromsolidtumorsapropensityscorematchedstudy